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Abstract
BACKGROUND: The development of an oral typhoid fever vaccine need more effective and having high-efficacy in 
preventing typhoid fever. The use of liposomes as a vaccine vehicle can be formulated to target a specific location 
or trigger the release of antigens on its target. β-Glucan derived from Candida albicans cell wall as immunoadjuvant 
can strengthen the immune response and increases the protection against Salmonella Typhi bacterial invasion.
AIM: This study aimed to determine the immune response in typhoid fever mice by administering a combination of 
AdhO36 S. Typhi liposome vaccine with β-Glucan and determine the protectivity to inhibit bacterial colonization in 
typhoid fever.
METHODS: Mice were divided into five groups include negative and positive control also treatment group. IL-12 
was evaluated after 4-h immunization while the other (was IL-12, IL-10, Th1 (IL-2), Th2 (IL-4), and the protective test 
against bacterial invasion) evaluated after 96-h.
RESULTS: IL-12 level in the combination of β-Glucan and AdhO36 groups showed significantly lower than infected 
groups (p = 0.034), whereas IL-10 level significantly increase (p = 0.0009). The percentage of Th-1 (IL-2) cells 
significantly lower than infected groups (p = 0.000), this also happened on the percentage of Th-2 (IL-4) cells that 
significantly lower than infected groups (p = 0.018). The protective test toward bacterial invasion showed no bacterial 
colonization in all tissues intestine, liver, spleen, and mesenteric lymph node.
CONCLUSION: The administration of a combination of liposome containing β-Glucan from C. albicans and AdhO36 
S. Typhi has a potential effect on cellular and humoral immune response.
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Introduction
As it has high morbidity, typhoid fever is an 
infectious disease that still becomes a health problem, 
especially in developing countries [1], [2]. Since 
the mortality is still high, the concern of controlling 
typhoid fever should be more aggressively through 
prevention [3]. Preventive measures by administering 
vaccines including Ty21a oral vaccine and ViCPS 
vaccine (Vi capsular polysaccharide) given parenterally 
have approximately between 51% and 67% efficacy, and 
in Indonesia, the use of enteric capsules dosage form 
has only 43% efficacy [4], [5]. Considering the protective 
power obtained from various known types of vaccines 
are still relatively low, the development of vaccines for 
controlling typhoid disease is highly needed. Vaccine 
development efforts are needed, particularly regarding 
proteins that play a role in bacterial immunity and 
virulence, namely, adhesin protein. Salmonella Typhi 
does not only have a fimbria adhesin protein called 
AdhF36 which plays a role in the attachment but also has 
an afimbrial adhesin protein called AdhO36 (afimbrial 
adhesin) which mediates a stronger attachment in host 
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cells [6], [7]. Adhesin protein mediates the attachment of 
bacterial cells to host cells, so it is a major virulence factor 
for bacteria. The present invention wishes to develop the 
potential of the AdhO36 adhesion protein further and 
combine it with the β-Glucan immunoadjuvant in oral 
dosage form since it has not been developed yet.
Physicochemical characteristics of active 
pharmaceutical ingredients or drug compounds in 
dosage forms or drugs and usage routes are critical 
determinants of in vivo performance, safety, and 
efficacy of medicinal products [8]. The drug’s properties 
and dosage forms are carefully designed and tested 
to produce the desired therapeutic response in 
patients. The importance of drug compounds and drug 
formulations is in the absorption and distribution of 
drugs to the site of action. The characteristics of drug 
ingredients or compounds determine the formulation, 
drug route, and bioavailability [9]. The dynamic stages 
of drug sequences that begin from entering through 
certain usage routes, drug release, and dissolution 
affect the absorption of the drug. Vaccine vehicle (VV) 
is used to determine the release and dissolution of the 
drug into the systemic circulation to the drug in the 
tissue results in pharmacological or clinical effects. 
The phase of developing VV by the oral route is 
needed primarily to prevent antigen degradation and 
increases the rate of absorption across the biological 
membrane, thereby increasing its bioavailability 
and therapeutic index [10], [11]. In this invention, 
the liposomal VV formulation is designed because 
liposome can be designed to target a specific location 
or trigger the antigen release on its target. The 
effectiveness of liposomal formulations depends on 
various physicochemical factors such as vesicle size, 
surface loading, bilayer composition, the presence of 
coatings, route of administration, use of adjuvants, the 
efficiency of encapsulation, and the composition of the 
lipids used [12], [13], [14].
In addition to the factor of increasing the 
effectiveness of vaccines by oral VV liposome, it is 
possible to manipulate by adding immunoadjuvant 
material that can strengthen the cellular immune system. 
Nowadays, there are many ingredients derived from 
nature that is potential as immunoadjuvant, one of which 
is β-Glucan that is a component of polysaccharides 
and is proven to be a potential immunoadjuvant [15]. 
β-Glucan is considered a stimulator of cellular immunity 
that activates macrophages. β-Glucan derived from 
Candida albicans cell walls can inhibit the colonization 
of Salmonella Typhimurium by potentiation in cellular 
immunity, namely, an increase in CD4+ and CD8+ 
levels [16], [17]. However, so far, there has no invention 
that tests whether β-Glucan administration in individuals 
who have been immunized with liposomal AdhO36 
formulation and given orally can increase the immune 
response.
In silico approach result has shown 
the potential effect of AdhO36 and beta-glucan 
combinations enhanced cellular immunity against 
S. Typhi infection [18]. The proposed invention on the 
use of a liposomal VV that is cationic in nature will 
provide a better delivery of the AdhO36 antigen system 
to the target cell, and immunoadjuvant administration 
can improve cellular and humoral immune responses 
so that the vaccine is more effective[19], [20].
Liposomes offer advantages as vaccine 
carriers compared to immuno-stimulating complex 
because they are able to increase the absorption of 
antigens in the intestinal area, as well as having good 
encapsulation efficiency values for hydrophilic and 
lipophilic antigens. AdhO36 antigens are hydrophilic, 
while β-glucan is a lipophilic immunoadjuvant [21], [22].
Materials and Methods
Culture and isolation of β-glucans from 
C. albicans
In this invention, C. albicans was obtained 
from vaginal clinical specimens and cultured in the 
sabouraud dextrose agar medium and incubated at 
37°C for 18–24 h. Gram-staining and observation 
were done under a microscope at ×1000, and germ 
tube tests were carried out to identify C. albicans. 
C. albicans culture obtained was soft, and creamy and 
had a special yeast odor. Microscopic analysis was 
performed by observing under a microscope at ×1000 
to ensure that C. albicans was cultured correctly. Gram-
staining and germ test tube culture of C. albicans were 
also performed and observed under ×1000.
C. albicans culture was harvested and collected 
by centrifugation at 3000× g with phosphate-buffered 
saline (PBS) pH 7.4. Cell pellets were collected and 
washed 5 times with lysis buffer (10 mM Tris-HCl 
combined with 1 mM phenyl-methyl-sulfonyl fluoride) 
and centrifuged at 3000× g for 10 min. Sediments were 
collected and suspended with lysis buffer at 4°C, and then 
mechanically lysed with 1-mm glass beads using Omni 
Mixer Homogenizer at 6000× g for 10 min. The lysed cells 
were separated by centrifugation at 3000× g for 10 min. 
The precipitate obtained was cell wall fraction [23].
Isolation of AdhO36 protein
S. Typhi was isolated from Saiful Anwar Public 
Hospital’s patient, Gram-negative and rod-shaped 
staining was identified. Identified S. Typhi bacteria were 
reproduced on the McConkey medium and incubated at 
37°C for 18–24 h. The culture from the McConkey medium 
was then transferred to the biphasic medium consisting 
of LB liquid medium and TCG sloping agar medium, 
incubated at 37°C for 24 h. Bacteria are harvested and 
used for the isolation of the AdhO36 protein. The liquid 
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culture from the biphasic medium was transferred into 
a 100 cc centrifuge tube, TCA was added so that the 
concentration was 3%, then centrifuged with PBS solution 
pH 7.4 sufficiently, then carried out the separation of the 
fimbria fraction using a modified fili cutting tool at 4°C, 
rotated at a temperature of 4°C 12,000 rpm for 15 min. 
The filtrate was separated (containing the fimbria fraction), 
while the sediment was suspended with sufficient PBS, 
then the fimbria was cut again. This process is repeated 
5 times. The cell fraction that has been separated from 
the fimbria fraction is suspended with sufficient PBS 
solution, and then a CHAPS detergent is added with a 
concentration of 5%. The mixture was vortexed for 5 min, 
and then centrifuged at 4°C 12,000 rpm for 15 min. 
The filtrate was taken (coarse Omp fraction), dialysis 
was performed using PBS dialysate in SDS-PAGE 
electrophoresis. Electrogram tape at a position of about 
36 kDa is cut and collected. Electroelution and dialysis 
were then applied to the gel pieces using PBS solution so 
that the pure protein AdhO36 was obtained [23]
VV formulation
Liposomal preparation was carried out using 
the thin-film hydration method based on the liposomal 
formula with the ovalbumin antigen model [24]. In 
the manufacturing process, DDA, soy phosphatidyl-
choline (SPC), and cholesterol were dissolved in 5 mL 
methanol. The lipid phase was the same for all formulas 
with a percentage of weight to the final volume of the 
preparation as follows: DDAB 0.025 g; SPC 0.091 g, and 
cholesterol 0.005 g. Then, the organic methanol solvent 
was removed using a rotary evaporator for 45–60 min 
at 45–55°C until a thin layer of lipid phase was formed 
on the wall of the round bottom flask. To form liposome, 
the thin film layer was hydrated with a solution of active 
ingredient β-Glucan or AdhO36. The dose of β-glucan 
was 300 μg, and the dose of AdhO36 100 μg.
In vivo test
The selected test animals were adult male 
mice aged 8 weeks weighing 20–30 g. There were five 
test groups, consisting of five mice in each group. The 
first group (A) negative control of uninfected mice, the 
second group (B) was positive control of infected mice 
with typhoid fever, the third group (C) was liposomal 
beta-glucan treatment group, the fourth group (D) was 
liposomal AdhO36 treatment group, and the fifth group 
(E) was combination of liposomal AdhO36 and liposomal 
beta-glucan combination treatment group. The positive 
and negative control groups received VV liposomal 
blank 3 times every 10 days. The beta-glucan treatment 
group received 300 μg of beta-glucan by oral route 3 
times every 10 days. As much as 300 mL 108 cells/mL 
of Salmonella Typhimurium were given twice in 2-day 
intervals [23], [25], [26]. Each group then evaluated 
using ELISA test 4 h after the last immunization to 
measure IL-12 level (Legend Max, USA, Cat. No. 
433607). After 96 h after last immunization, IL-10 level 
(Legend Max, USA, Cat. No. 431417) of all groups 
was tested using ELISA method and further evaluated 
Th1 (IL-2) and Th2 (IL-4) level using flow cytometry. 
Colonization of bacteria tested in some organs such 
as intestine, liver, spleen, and mesenteric lymph node 
(MLN) [25]. The percentage of IL-2 (Th1) and IL-10 
(Th2) was measured using intracellular staining of flow 
cytometry [27]. Briefly, the spleen tissues were isolated 
and single cell suspensions were prepared. The tissue 
was passed through a nylon mesh (70 μm pore size). For 
intracellular cytokine measurement, spleen cells (1×106) 
were stimulated for 5 h with PMA (1 μg/mL, Sigma-
Aldrich) and ionomycin (50 μg/mL, BD Biosciences) in 
the presence of monensin (0.1 mg/mL, Sigma-Aldrich) 
and incubated in a 37°C and 5% CO2. Spleenic cells 
were washed with PBS and surface-labeled with 
anti-CD4–FITC (Biolegend, Uithoorn, Netherlands). 
Cells were fixed and permeabilized (Cytofix/Cytoperm, 
BD Biosciences) and stained with anti-IL-2-PE 
(Biolegend, Uithoorn, Netherlands, cat No. 503808) and 
anti-IL-4-PE (Biolegend, Uithoorn, Netherlands, cat. 
No. 504104). After fixation, three-color cytometry was 
done using a FACSCalibur flow cytometer. A minimum 
of 10,000 cell-gate events were acquired and analyzed 
with CELL Quest (Becton Dickinson) software.
This study has obtained the Ethical Clearance 
from University of Muhammadiyah Malang Indonesia, 
as stated through decree No.E.5.a/136/KEPK-UMM/
VII/2019.
Results
The combination of β-glucan and AdhO36 
decrease IL-12 levels
IL-12 levels were examined from plasma 
examination material using the ELISA method, and 
Figure 1: The combination of β-Glucan and AdhO36 decrease IL-12 
levels (A2: Uninfected control, B2: Infected control, C2: Liposomal 
β-Glucan, D2: Liposomal AdhO36, E2: Liposomal β-Glucan-AdhO36)
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the absorbance data were converted to levels. From 
Figure 1 and the ANOVA analysis results in p = 0.030, 
there were significant differences in IL-12 levels in the 
treatment of each group. From Tukey HSD test, it was 
found that in the healthy Group (A) and the infected 
Group (B), there were no significant differences but 
there was a tendency to be higher. This result shows 
that mice were not able to increase cellular immune 
response. Same result happened on infected Group 
(B), treatment Group C (β-Glucan), and the treatment 
Group D (AdhO36) that there were no significant 
differences. While result of Group E (combination 
β-Glucan + AdhO36), there was a significant difference 
compared to the infected control group (p = 0.034).
The combination of β-glucan and AdhO36 
increase IL-10 levels
IL-10 is a type 2 cytokine that stimulates humoral 
immunity by stimulating the development and activation 
of mast cells and eosinophils, differentiation of B cells 
to secrete antibodies and switching immunoglobulin B 
cells to IgE. IL-10 is a very important cytokine because 
it inhibits macrophage activation, T cell proliferation, 
and pro-inflammatory cytokine production (Elenkov IJ, 
Chrousos GP and Wilder RL, 2014). IL-10 parameters 
in the research results obtained that in treatment E 
(β-Glucan + AdhO36), the average IL-10 level was the 
highest compared to other treatments and statistically 
significant.
IL-10 levels were measured using a plasma 
examination material in the 96-h group using the 
ELISA method, and the results that were absorbance 
were converted to levels. ANOVA analysis results can 
be seen in the Group (E) combination of β-glucan and 
AdhO36 liposomes compared to the infected group 
(p = 0.0009) (Figure 2).
The combination of β-glucan and AdhO36 
decrease the percentage of Th-1 (IL-2) cells
The percentage of Th-1 (IL-2) cells was 
examined from spleen examination material in the 
96-h group using the flow cytometry method, and 
the data analyzed were the percentage of Th-1 
(IL-2) cell (UR% Gated). From Figure 3 and ANOVA 
analysis results, it can be seen that the treatment 
in all treatment groups and E (β-Glucan + AdhO36) 
results in a significant difference to (B) infected group 
(p = 0.000).
Figure 3: Combination of β-Glucan and AdhO36 decrease the 
percentage of Th-1 (IL-2) cells. (a) Result the percentage of Th-1 
(IL-2) cells were examinated using flow cytometry (b). Histogram 
ANOVA analysis results. (A) uninfected control (B) infected control 
(C) Liposomal β-Glucan (D) Liposomal AdhO36 (E) Liposomal 
β-Glucan-AdhO36
b
a
The combination of β-glucan and AdhO36 
decrease the percentage of Th-2 (IL-4) cells
The percentage of Th-2 (IL-4) cells were 
examined from the spleen examination material in the
Figure 4: Combination of β-Glucan and AdhO36 decrease the 
percentage of Th-2 (IL-4) cells. (a) Result the percentage of Th-2 
(IL-4) cells were examinated using flow cytometry (b). Histogram 
ANOVA analysis results. (A) uninfected control (B) infected control 
(C) Liposomal β-Glucan (D) Liposomal AdhO36 (E) Liposomal 
β-Glucan-AdhO36
b
a
Figure 2: Combination of β-Glucan and AdhO36 Increase IL-10 levels. 
(A) uninfected control (B) infected control (C) Liposomal β-Glucan (D) 
Liposomal AdhO36 (E) Liposomal β-Glucan-AdhO36
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96-h group using the flow cytometry method, and the 
data analyzed were percentage of Th-2 (IL-4) cell (UR% 
Gated). From Figure 4 and ANOVA analysis results, it 
can be seen that in the treatment Group E (β-Glucan 
+ AdhO36), there is a significant difference to infected 
group (p = 0.018).
The combination of β-glucan and AdhO36 
is protective to bacterial invasion in all tissues 
(intestine, liver, spleen and MLN)
The samples used were obtained from organs 
(intestine, liver, spleen, and MLN) of mice which were 
immunized according to treatment 3 times with an 
interval of 10 days and infected twice with a 2-day 
interval with 108 cells/mL S. Typhimurium as much as 
300 μL after 96 h of organ surgery. The parameters used 
to measure the effectiveness of liposomal β-Glucan, 
liposomal AdhO36, and combination treatment of 
β-Glucan and AdhO36 liposomal are colonization count 
bacteria that are still alive in the intestine (U), liver (H), 
spleen (L), and MLN: Mesenteric Lymphoid Node (M) 
(Figure 5).
Discussion
IL-12 is produced by dendritic cells (DC), 
macrophages, neutrophils, microglia cells, and a small 
number of B cells. IL-12 is a cytokine that initiates 
cellular immune responses associated with inhibition of 
bacterial invasion. IL-12 is produced as a response to 
intracellular microbe infection. IL-12 plays an important 
role in the control of infections by intracellular bacteria 
such as Salmonella sp. IL-12 plays a protective role 
in host-defense against Salmonella sp. Secretion 
of IL-12 increases markedly after Salmonella sp. 
infection [28]. IL-12 will induce T-lymphocytes and NK 
cells to produce INF-γ. IFN- γ is produced by Th1 cells 
and promote cell-mediated immunity, which is essential 
for the response against intracellular pathogens. IL-12 
is the main cytokine that regulates Th1 differentiation 
and has a number of important actions that serve to 
promote cell-mediated immunity. From the results of 
the study (Figure 1), the average IL-12 level in Group 
B (infected) was 5.798 (pg/mL), which is higher than 
Group A (healthy). This shows that IL-12 concentrations 
increase because IL-12 is produced by macrophages 
and infected DC; IL-12 is produced in response to various 
microbial stimuli including LPS, infection by intracellular 
bacterial and viral infections. The IL-12 cytokine is the 
main cytokine that activates STAT4, which will induce 
Th1 cellular responses. From the results of the study, it 
was found that IL-12 level in the Group E (β-Glucan and 
AdhO36) showed the lowest result compared to other 
treatments but obtained the highest IL-10 level, this is 
consistent with the theory that IL-12 is an intermediary 
inhibiting IL-12 production. IL-10 is a potent inhibitor of 
IL-12 production of accessory cells [29].
The results of this invention show that β-Glucan 
can increase IL-10 level. IL-10 is known for its ability 
to inhibit activation and effector functions of T cells, 
monocytes, and macrophages. The main function of 
IL-10 in the body’s immune system is to inhibit the Th-1 
response. IL-10 is a type 2 cytokine that stimulates 
humoral immunity by stimulating the development 
and activation of mast cells and eosinophils, and 
differentiating B cells to secrete antibodies and 
switching immunoglobulin B cells to IgE. IL-10 is a 
very important cytokine because it inhibits macrophage 
activation, T cell proliferation, and pro-inflammatory 
cytokine production.
The cytokines secreted by Th1 are IL-2, IFN-y, 
and TNF-α that encourage cellular immunity, whereas 
the cytokines secreted by Th-2 are IL-4, IL-5, IL-6, 
and IL-10. IFNγ secretion will inhibit Th-2 cells while 
IL-10 secretion will inhibit Th-1 cells. The results of this 
study theoretically agree that the presence of protein 
antigens producing TCD4+ cell responses stimulates 
differentiation of both Th-1 and Th-2. In the treatment 
groups, the combination of liposomal β-glucan and 
liposomal AdhO36 obtained higher average levels 
than healthy and infected controls. This shows that the 
potential of β-glucan in increasing IL-10 levels. IL-10 is 
known for its ability to inhibit the activation and function 
of T-cell, monocyte, and macrophage effectors. The 
main function of IL-10 in the body’s immune system is 
to inhibit the Th-1 response.
Research results obtained that in treatment E 
(β-Glucan + AdhO36) the average IL-10 level was the 
highest and statistically significant compared to other 
treatments. The cytokines secreted by Th1 are IL-2 
and IFN-y while the cytokines secreted by Th-2 are 
IL-4, IL-5, IL-6, and IL-10. IFN-γ secretion will inhibit 
Th-2 cells while IL-10 secretion will inhibit TH-1 cells. 
The results of this study theoretically agree that the 
presence of protein antigens producing TCD4+ cell 
responses stimulates the differentiation of both Th-1 
and Th-2. In the liposomal β-glucan and liposomal 
AdhO36 treatment group, each level was found to 
Figure 5: The combination of β-Glucan and AdhO36 is protective to 
bacterial invasion in all tissues (intestine, liver, spleen, and MLN). 
(A) uninfected control (B) infected control (C) Liposomal β-Glucan 
(D) Liposomal AdhO36 (E) Liposomal β-Glucan-AdhO36
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be higher than the healthy or infected controls. This 
shows that the potential of β-glucan in increasing IL-10 
levels. IL-10 is known for its ability to inhibit activation 
and function of T-cell, monocyte and, macrophage 
effectors. The main function of IL-10 in the body’s 
immune system is to inhibit the Th-1 response. IL-10 
is a type 2 cytokine that stimulates humoral immunity 
by stimulating the development and activation of mast 
cells and eosinophils, differentiation of B cells to secrete 
antibodies and switching immunoglobulin B cells to IgE. 
IL-10 is a very important cytokine because it inhibits 
macrophage activation, T cell proliferation, and pro-
inflammatory cytokine production [30].
The cytokines secreted by Th2 are IL-4, IL-5, 
IL-6, and IL-10. From the results of the in vivo test, 
IL-10 obtained by treatment Group E (combination of 
beta-glucans and AdhO36) increased. IL-10 expressed 
can come from antigen-presenting cell (APC) which is 
activated by an antigen, in this case AdhO36. Naive 
CD+T cell differentiation into Th2 cells is stimulated 
by IL-4, IL-10. From the research results, the 
administration of β-Glucan has been shown to increase 
TCD4 + cells [23].
From the histogram of the number of bacterial 
colonies and ANOVA analysis results, it was found that 
overall in the treatment groups there were significant 
differences between in intestine, liver, and spleen 
(p = 0.000 <0.05) while in MLN there were no significant 
differences (p = 0.153> 0.05). The results of the 
post hoc Tukey test on the number of bacterial colonies 
in the intestine, liver, and spleen results showed that 
there were significant differences (p = 0.000 <0.05) 
in the number of colonies with (C) liposomal β-glucan 
treatment, (D) liposomal AdhO36, and (E) combination 
of β-glucan and AdhO36 liposomes against infected 
control (B).
Protection test against bacterial invasion 
from the research results of (C) liposomal β-glucan, 
(D) liposomal AdhO36 treatment, and (E) combination 
of liposomal β-glucan and AdhO36 shows that the 
treatment can reduce or colonization of bacteria does 
not occur in the intestine, liver, lien, and MLN. In infected 
control mice, the amount of colonization in the intestine 
is very high, while in the liver and in the spleen, the 
amount of colonization is quite a lot, but in MLN there 
is little colonization. The results showed no colonization 
in the intestine, liver, spleen, and MLN. This shows that 
the treatment can inhibit the invasion of bacteria into 
organs.
From the results of the study, the administration 
of liposomal β-glucan treatment provides good 
protection in inhibiting colonization in the intestine, 
liver, spleen, and MLN. This is different from the results 
of the study by Winarsih et al. (2019), administration 
of β-glucan extract from the cell wall of C. albicans 
300 μg/day 1 time on day 5–day 9 after the mice were 
infected with S. Typhimurium orally 108 cells/mL on day 
1 and day 3 indicates colonization. Liposomal Β-glucan 
formulation gives better results, this could be due to the 
particle size in the nanoform that allows cellular uptake 
and is specific so that the nanoparticle liposomal 
β-glucan is more effective in uptake for migration by 
DC. The charge on the liposomal cationic surface can 
also change the surface of the anionic membrane 
cell so that this interaction between electro-statistics 
leads to an internalization efficiency by APC [31]. From 
biopharmaceutical research, it showed that B-glucan 
affects the immune system through binding of the cell 
receptor of APC named Dectin-1 and TLR-2 [18]. This 
APC will serve antigen to lymphocyte, and the immune 
system of the body will be inducted to fight infection.
Potential of β-Glucan as immunoadjuvant is 
proven; the combination of liposomal β-glucan and 
AdhO36 provides protection and inhibits invasion and 
colonization in the intestine, liver, spleen, and MLN. 
Β-glucan from several studies provides evidence of 
immunoadjuvant because it is used to increase the 
efficacy of vaccines and can stimulate specific immunity. 
Immunoadjuvant is used in cellular immunity and 
humoral immunity. The immune response mechanism 
starts from the APC. This is a crucial stage in activating 
the immune system. The best APC responsible for 
activation of T cells, NK cells, and B cells is DC (Jin 
et al., 2018; Patel, 2012). Two main types of cellular 
immune reactions that eliminate different types of 
microbes: CD4+ helper T cells + secrete cytokines that 
recruit and activate other leukocytes to phagocytosis 
(digest) and destroy microbes, and CD8+ cytotoxic 
T lymphocytes kill infected cells and contain other 
microbial proteins in the cytosol, eliminating cellular 
sources of infection. Cellular immunity protects against 
infections caused by intracellular bacteria. From the 
research results, the Th1/Th2 ratio where Th1% Gated 
(UR) is lower than Th2, 0.582 compared to 1.034, 
respectively (Figures 3 and 4). Th-1 cells secrete INF-γ, 
IL-2, and TNF-β which encourage cellular immunity. 
IL-12 is produced by APCs and activated monocytes 
or macrophages. IL-12 and TNF-α encourage Th-1 cell 
responses and cellular immunity. Th-2 cells secrete IL-4, 
IL-10, and IL-13 which encourage the humoral immune 
response. Th-1 and Th-2 responses alternately inhibit 
their secretion [30]. The presence of β-glucan increases 
the activation of macrophages and DC (Kim et al., 2011); 
this indirectly proves that IL-12 secretion increases with 
β-Glucan and increases Th-1, an increase in Th-1 will 
be downregulation by IL-10. Results in Figure 2 show 
the highest levels of IL-10 in the combination treatment 
of liposomal β-glucan and AdhO36. Increased IL-10 
will increase the humoral immune response, and the 
colonization test proved to be no colonization in the 
intestine, liver, spleen, and MLN.
From the results of the study shown in Figure 2, 
in the treatment (E) combination of liposomal β-glucan 
and AdhO36, IL-10 level is smaller than the treatment 
(D). This is likely due to the interaction of physics, 
chemistry, and pharmacology. This can be seen from 
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the results of β-Glucan studies on transport in the 
gastrointestinal tract that shows the transfer rate to its 
gut ranges between 0.5 and 12 h. The physicochemical 
characteristics of β-glucan determine this transfer 
rate. From the results of the flow analysis, β-glucan 
was added in cells after 24 h. The first cells that can 
swallow glucan are the small intestinal epithelial cells 
and only 10% can internalize; this is likely a specific 
subpopulation where intestinal cells can transfer 
glucan [32]. From the results of the study above, the 
characteristics of β-glucan from the C. albicans cell wall 
to determine β-Glucan transport in the small intestine 
are needed. The results of this study indicate that the 
potential of β-glucan as immunoadjuvant is proven 
by increasing cellular immune response and humoral 
immune response. However, it is needed to develop 
oral β-glucan liposomal preparations added to AdhO36 
related to physical, chemical, and pharmacological 
interactions to obtain an oral typhoid fever vaccine that 
is stable, comfortable, safe, and effective and has high 
efficacy.
Conclusion
The administration of a combination of β-glucan 
liposome from C. albicans and AdO36 Salmonella Typhi 
has a potential effect on cellular and humoral immune 
response. The β-glucan potential of C. albicans as 
immunoadjuvant has been shown to increase the 
immune response.
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